▲ 1.33%
prev close
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Congressional Trades
1
All tracked trades
Members Trading
1
Unique members
Net Activity
-1
0 buys · 1 sells
Members Who Traded This Stock
1 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2023-03-06 | BMRNBioMarin Pharmaceutical Inc. | Sell | $1,001 - $15,000 | 1081d ago | — |
2023-03-06
Daniel Goldman
BMRN
Amount
$1,001 - $15,000
Filed
1081d ago
Recent News
Powered by Polygon.io
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally
BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz
Skeletal Dysplasia Market - Global Forecast 2026-2032: $5.37 Bn Opportunities Driven by Advancing Diagnostic Precision, Integrated Therapies, Evidence Generation, and Equitable Access
BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026
Trade Timeline
Congressional activity, newest first
Daniel Goldman
2023-03-06 · Sale
$1,001 - $15,000